TEANECK, N.J. / Sep 05, 2023 / Business Wire / Phibro Animal Health Corporation (Nasdaq:PAHC) (“Phibro” or the “Company”) today announced that Damian Finio, Phibro’s Chief Financial Officer, has informed the Company that he will resign from his position effective September 29, 2023.
Phibro also announced that Richard G. Johnson, who previously served as the Company’s Chief Financial Officer from 2002 until his retirement from this position in 2020, and has continued to serve as Finance Advisor to the Company, will work with Mr. Finio over the next few weeks to ensure a smooth transition. Mr. Johnson will assume the role of interim Chief Financial Officer of the Company effective as of September 30, 2023 until a successor to Mr. Finio is identified.
“I want to take this opportunity to recognize and thank Damian for his many contributions during his tenure as Chief Financial Officer of Phibro and wish him success in his future endeavors,” said Jack Bendheim, Phibro’s Chairman, President and Chief Executive Officer. “I am also pleased to announce that Richard G. Johnson, who served as Phibro’s Chief Financial Officer for more than 18 years, and has continued to provide insight and guidance as a Finance Advisor to the Company since 2020, will be filling the role of Interim Chief Financial Officer as we search for a replacement. Richard brings extensive knowledge of the industry and our business that will allow us to transition smoothly during this process.”
About Phibro Animal Health Corporation
Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. For further information, please visit www.pahc.com.
Last Trade: | US$20.49 |
Daily Change: | -1.57 -7.12 |
Daily Volume: | 285,864 |
Market Cap: | US$416.770M |
January 23, 2025 August 28, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load